Thu Jul 24 04:08:00 SGT 2014  
HEPATITIS
B
    Hepatitis B, Jamaica
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Hepatitis B, Jamaica

Summary

Hepatitis B, Jamaica @hepatitisb_biz: Hepatitis B symptoms in men/women, screening/diagnosis, testing/check and treatment, Jamaica - Private and confidential service.

Keywords: Hepatitis B Jamaica, Jamaica Hepatitis B, Hepatitis B.

Description

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
HIV STD TESTING TREATMENT™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Hepatitis B, Jamaica
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Budget airlines based in Singapore:

Budget airlines operating in Singapore:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

Location reference


Latest News

Entecavir Does Not Eliminate HCC Risk in Hepatitis B PatientsEntecavir Does Not Eliminate HCC Risk in Hepatitis B Patients
Wed, 23 Jul 2014 02:15:58 +0100 | Medscape Gastroenterology Headlines
Patients taking entecavir for chronic hepatitis B are still at risk for hepatocellular carcinoma (HCC), a recent study suggests. Reuters Health Information (Source: Medscape Gastroenterology Headlines)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology
Wed, 23 Jul 2014 02:12:40 +0100 | Anais Brasileiros de Dermatologia
We report the case of a patient with severe psoriasis with positive serology for the Hepatitis B virus, who received ustekinumab (a human monoclonal antibody against interleukin 12 and 23). In this patient, the use of ustekinumab did not reactivate the Hepatitis B virus. Given the high prevalence of chronic viral infections in patients who are candidates for biologic therapy, as well as the potential for reactivate chronic viral illness, randomized controlled studies are needed to assess the risks and benefits of such therapy in these populations. (Source: Anais Brasileiros de Dermatologia)

Methylation of suppressor of cytokine signalling 1 gene promoter is associated with acute‐on‐chronic hepatitis B liver failure
Tue, 22 Jul 2014 00:15:37 +0100 | Journal of Viral Hepatitis
This study was therefore to identify the potential role of SOCS1 and its promoter methylation pattern in ACHBLF patients. Sixty ACHBLF patients, 60 chronic hepatitis B (CHB) patients and 30 healthy controls were investigated in this study. We found that expression of SOCS1 mRNA in CHB and ACHBLF patients was significantly higher than that in healthy controls. The serum level of IL‐6, IFN‐γ and TNF‐α was significantly higher in ACHBLF than CHB. Increased serum level of IL‐6, IFN‐γ and TNF‐α was correlated with total bilirubin, ALT, PTA and MELD scores in ACHBLF. The degree of methylation of the SOCS1 in ACHBLF patients (35.0%, 21/60) was significantly higher than that in CHB patients (16.7%, 10/60). Furthermore, methylated group showed lower level of SOCS1, and higher MELD s...

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections
Mon, 21 Jul 2014 00:00:00 +0100 | Hepatology

Safe and cost‐effective control of post‐transplantation recurrence of hepatitis B
Fri, 18 Jul 2014 00:00:00 +0100 | Hepatology Research
This article reviews recent advances in post‐OLT hepatitis B virus (HBV) control and future methodological directions. New NUC such as entecavir, tenofovir or lamivudine plus adefovir dipivoxil combinations induce a very low frequency of viral resistance. The withdrawal of HBIG after several months of OLT under new NUC continuation also has permissible effects. Even after HBV reactivation, NUC can usually achieve viral control when viral markers are strictly followed up. Another approach is to induce self‐producing anti‐HBV antibodies via vaccination with a hepatitis B surface antigen vaccine. However, HBV vaccination is not sufficiently effective in patients to treat liver cirrhosis type B after OLT because immune tolerance to the virus has already continued for several decades. Tri...

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study.
Fri, 18 Jul 2014 00:00:00 +0100 | Vaccine
CONCLUSIONS: GS-4774 was safe and well-tolerated in healthy subjects with injection-site reactions being the most frequently reported adverse events. With both weekly and monthly regimens, GS-4774 provided HBV-specific immune responses at all doses evaluated. Further evaluation of GS-4774 is ongoing in patients with chronic HBV infection. Clinical trial registry: Clinicaltrials.gov (NCT01779505).

Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.
Fri, 18 Jul 2014 00:00:00 +0100 | Vaccine
CONCLUSIONS: We identified four HIV vaccine attitude scales with sound internal reliability parameters. In the aftermath of the first candidate vaccine to demonstrate efficacy against HIV infection, these scales may be helpful in bridging expectable research-to-practice gaps in future HIV vaccine dissemination among populations at risk. As HIV vaccine trials progress in the United States and globally, these measures also may be useful as a tool to assess and facilitate effective responses to community concerns about HIV vaccine trials and to target interventions to support recruitment and mitigate risk compensation.

Early Childhood Hep B Vaccine Gives Long-Term ProtectionEarly Childhood Hep B Vaccine Gives Long-Term Protection
Thu, 17 Jul 2014 11:33:36 +0100 | Medscape Medical News Headlines
Immunity to hepatitis B after primary immunization in early childhood gives long-term protection, a new study suggests. Reuters Health Information (Source: Medscape Medical News Headlines)

Diagnostic value of circulating microRNAs for hepatocellular carcinoma.
Thu, 17 Jul 2014 00:00:00 +0100 | Molecular Biology Reports
Authors: Yang Y, Zhu R

The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US
Wed, 16 Jul 2014 00:00:00 +0100 | Alimentary Pharmacology and Therapeutics
ConclusionsPresence of type 2 diabetes pre‐ and post‐transplant, as well as presence of type 2 diabetes in the donors type 2 diabetes are all associated with an increased risk of adverse post‐transplant outcomes. (Source: Alimentary Pharmacology and Therapeutics)